pioglitazone has been researched along with HIV Lipodystrophy Syndrome in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Excerpt | Relevance | Reference |
---|---|---|
"Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance." | 9.15 | Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011) |
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance." | 7.72 | Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004) |
"Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance." | 5.15 | Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011) |
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance." | 3.72 | Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004) |
"Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS." | 2.46 | The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. ( Larson, RJ; Sheth, SH, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Okada, S | 1 |
Konishi, M | 1 |
Ishii, H | 1 |
Sheth, SH | 1 |
Larson, RJ | 1 |
Magkos, F | 1 |
Brennan, A | 1 |
Sweeney, L | 1 |
Kang, ES | 1 |
Doweiko, J | 1 |
Karchmer, AW | 1 |
Mantzoros, CS | 1 |
Calmy, A | 1 |
Hirschel, B | 1 |
Hans, D | 1 |
Karsegard, VL | 1 |
Meier, CA | 1 |
Prasithsirikul, W | 1 |
Bunnag, P | 1 |
Slama, L | 1 |
Lanoy, E | 1 |
Valantin, MA | 1 |
Bastard, JP | 1 |
Chermak, A | 1 |
Boutekatjirt, A | 1 |
William-Faltaos, D | 1 |
Billaud, E | 1 |
Molina, JM | 1 |
Capeau, J | 1 |
Costagliola, D | 1 |
Rozenbaum, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients[NCT00140244] | Phase 2 | 7 participants (Actual) | Interventional | 2001-12-31 | Completed | ||
A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study[NCT00148850] | Phase 3 | 130 participants | Interventional | 2003-02-28 | Terminated | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
percent change in mean blood pressure (NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | percentage change of mean blood pressure (Least Squares Mean) |
---|---|
r-MetHuLeptin | 3.2 |
Placebo | -6.7 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | cells/mcl (Mean) |
---|---|
r-MetHuLeptin | 556.6 |
Placebo | 637.2 |
Fibrinogen (NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | mg/dL (Mean) |
---|---|
r-MetHuLeptin | 252.2 |
Placebo | 294.4 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | mEq/liter (Mean) |
---|---|
r-MetHuLeptin | 0.45 |
Placebo | 0.61 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | mg/dl (Mean) |
---|---|
r-MetHuLeptin | 91 |
Placebo | 95.6 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | percentage of liver volume (Mean) |
---|---|
r-MetHuLeptin | 4.02 |
Placebo | 4.01 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | mcIU/ml (Mean) |
---|---|
r-MetHuLeptin | 11.6 |
Placebo | 20.3 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | units on a scale (Mean) |
---|---|
r-metHuLeptin | 2.52 |
Placebo | 4.56 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | pg/ml (Mean) |
---|---|
r-MetHuLeptin | 1.65 |
Placebo | 2.14 |
lean body mass (NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | kg (Mean) |
---|---|
r-MetHuLeptin | 58.6 |
Placebo | 61.6 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | mg/dl (Mean) |
---|---|
r-MetHuLeptin | 113 |
Placebo | 105.7 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | copies/ml (Mean) |
---|---|
r-MetHuLeptin | 11345 |
Placebo | 12367 |
(NCT00140244)
Timeframe: At the end of each two month intervention
Intervention | mg/dl (Mean) | ||||
---|---|---|---|---|---|
total cholesterol | low density lipoprotein cholesterol | triglycerides | high density lipoprotein cholesterols | Free fatty acids | |
Placebo | 219.7 | 105.7 | 520.5 | 29.96 | 0.61 |
r-MetHuLeptin | 228.8 | 113.0 | 409.0 | 35 | 0.45 |
1 review available for pioglitazone and HIV Lipodystrophy Syndrome
Article | Year |
---|---|
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistanc | 2010 |
3 trials available for pioglitazone and HIV Lipodystrophy Syndrome
Article | Year |
---|---|
Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
Topics: Adiponectin; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Mass Index; Drug Ther | 2011 |
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
Topics: Adult; Anthropometry; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infectio | 2003 |
Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
Topics: Adult; Double-Blind Method; Female; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycem | 2008 |
2 other studies available for pioglitazone and HIV Lipodystrophy Syndrome
Article | Year |
---|---|
Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.
Topics: Antiretroviral Therapy, Highly Active; Body Fat Distribution; HIV-Associated Lipodystrophy Syndrome; | 2016 |
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch | 2004 |